-
公开(公告)号：US06174914B1
公开(公告)日：2001-01-16
申请号：US09333454
申请日：1999-06-15
申请人： John M. Yanni , Daniel A. Gamache , Lori K. Weimer
发明人： John M. Yanni , Daniel A. Gamache , Lori K. Weimer
IPC分类号： A61K31335
CPC分类号： A61K31/335
摘要： Ophthalmic formulations containing as an active ingredient 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid or a pharmaceutically acceptable salt thereof are useful for inhibiting cytokine release (e.g., IL-6 and IL-8) from human ocular cells. Such formulations can be used to treat or prevent ocular neovascularization and non-allergic inflammatory disorders such as dry-eye, keratitis, blepharitis, uveitis and inflammation related to infection.
摘要翻译： 含有作为活性成分的11-（3-二甲基氨基亚丙基）-6,11-二氢二苯并[b，e]氧杂七环素-2-乙酸或其药学上可接受的盐的眼用制剂可用于抑制细胞因子释放（例如IL-6和 IL-8）。 这样的制剂可用于治疗或预防眼睛新生血管形成和非过敏性炎症性疾病如干眼症，角膜炎，睑炎炎，葡萄膜炎和与感染相关的炎症。
-
2.发明授权Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders 失效含有二十二碳四烯酸衍生物的组合物和用于治疗干眼症的方法公开(公告)号：US06353022B1
公开(公告)日：2002-03-05
申请号：US09694796
申请日：2000-10-23
申请人： L. Wayne Schneider , Daniel A. Gamache , Lori K. Weimer , Timothy L. Kessler , Zhongyou Wei , Terri Pasquine , John M. Yanni , Haresh G. Bhagat
发明人： L. Wayne Schneider , Daniel A. Gamache , Lori K. Weimer , Timothy L. Kessler , Zhongyou Wei , Terri Pasquine , John M. Yanni , Haresh G. Bhagat
IPC分类号： A61K31215
摘要： Compositions containing one or more HETE derivative(s) and an effective concentration of ethanol and methods of use for treating dry eye are disclosed.
摘要翻译： 公开了含有一种或多种HETE衍生物和有效浓度的乙醇的组合物和用于治疗干眼症的方法。
-
3.发明申请公开(公告)号：US20120065187A1
公开(公告)日：2012-03-15
申请号：US13301131
申请日：2011-11-21
申请人： Allen J. Borchardt , Clay Beauregard , Travis Cook , Robert L. Davis , Daniel A. Gamache , John M. Yanni
发明人： Allen J. Borchardt , Clay Beauregard , Travis Cook , Robert L. Davis , Daniel A. Gamache , John M. Yanni
IPC分类号： A61K31/4985 , A61K31/55 , A61K31/551 , A61K31/5415 , A61P11/06 , A61P37/00 , A61P37/08 , A61P27/02 , A61P17/04 , A61P17/00 , C07D487/04 , A61P29/00
CPC分类号： C07D487/04 , C07D471/04 , C07D498/04 , C07D519/00
摘要： The present invention relates to compounds and methods which may be useful as inhibitors of H1R and/or H4R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.
摘要翻译： 本发明涉及可用作H1R和/或H4R抑制剂用于治疗或预防炎性，自身免疫性，过敏性和眼部疾病的化合物和方法。
-
4.发明申请RNAi-Mediated Inhibition of Spleen Tyrosine Kinase-Related Inflammatory Conditions 有权RNAi介导的脾脏酪氨酸激酶相关炎症病症的抑制公开(公告)号：US20110288157A1
公开(公告)日：2011-11-24
申请号：US13172964
申请日：2011-06-30
IPC分类号： A61K31/7105 , A61P27/02 , A61K31/713 , A61P29/00
CPC分类号： C12N15/1137 , A61K31/7105 , A61K31/713 , C07H21/02 , C12N15/113 , C12N2310/14 , C12N2310/531 , C12N2320/30
摘要： RNA interference is provided for inhibition of spleen tyrosine kinase (Syk) mRNA expression, in particular, for treating patients having a Syk-related inflammatory condition or at risk of developing a Syk-related inflammatory condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, allergy, or mast-cell disease.
摘要翻译： 提供RNA干扰用于抑制脾脏酪氨酸激酶（Syk）mRNA表达，特别是用于治疗患有Syk相关炎性病症的患者或具有发展Syk相关炎性病症如过敏性结膜炎，眼部炎症，皮炎， 鼻炎，哮喘，过敏或肥大细胞疾病。
-
公开(公告)号：US20100081646A1
公开(公告)日：2010-04-01
申请号：US12544185
申请日：2009-08-19
申请人： Steven P. Govek , Clay Beauregard , Daniel A. Gamache , Mark R. Hellberg , Stewart A. Noble , Andrew K. Shiau , David J. Thomas , John M. Yanni
发明人： Steven P. Govek , Clay Beauregard , Daniel A. Gamache , Mark R. Hellberg , Stewart A. Noble , Andrew K. Shiau , David J. Thomas , John M. Yanni
IPC分类号： A61K31/551 , C07D401/12 , C07D413/14 , C07D401/14 , A61K31/4709 , A61K31/497 , A61K31/5377 , A61P27/02 , A61P37/00
CPC分类号： A61K31/4704 , A61K31/4709 , A61K31/497 , A61K31/5377 , A61K31/551 , A61K45/06 , C07D401/12 , A61K2300/00
摘要： The present invention relates to compounds and methods which may be useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.
摘要翻译： 本发明涉及可用作磷酸二酯酶4（PDE4）抑制剂的化合物和方法，用于治疗或预防炎性疾病和涉及升高的细胞因子和促炎介质水平的其它疾病。
-
6.发明申请AMINOPYRIMIDINE INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE 审中-公开用于治疗疾病的组胺受体的氨基嘧啶抑制剂公开(公告)号：US20100063047A1
公开(公告)日：2010-03-11
申请号：US12556842
申请日：2009-09-10
IPC分类号： A61K31/5377 , C07D495/04 , A61K31/497 , A61K31/519 , A61K31/4365
CPC分类号： C07D495/04 , A61K9/0043 , A61K9/0048 , A61K9/0073 , A61K31/4365 , A61K31/497 , A61K31/519 , A61K31/5377 , A61K45/06 , A61K2300/00
摘要： The present invention relates to compounds and methods which may be useful as inhibitors of H1R and/or H4R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.
摘要翻译： 本发明涉及可用作H1R和/或H4R抑制剂用于治疗或预防炎性，自身免疫性，过敏性和眼部疾病的化合物和方法。
-
7.发明申请USE OF TRPV1 RECEPTOR ANTAGONISTS FOR TREATING DRY EYE AND OCULAR PAIN 审中-公开TRPV1受体拮抗剂用于治疗干眼症和眼部疼痛的应用公开(公告)号：US20090131449A1
公开(公告)日：2009-05-21
申请号：US12273047
申请日：2008-11-18
申请人： John M. Yanni , Daniel A. Gamache
发明人： John M. Yanni , Daniel A. Gamache
IPC分类号： A61K31/497
CPC分类号： A61K31/497 , A61K31/506
摘要： Methods of treating symptoms of dry eye by administering inhibitors of transient receptor potential cation channel, subfamily V, member 1 (TRPV1) are disclosed. Methods of preventing or alleviating ocular pain by administering TRPV1 inhibitors are also disclosed.
摘要翻译： 公开了通过施用瞬时受体潜在阳离子通道的抑制剂V，成员1（TRPV1）来治疗干眼症状的方法。 还公开了通过施用TRPV1抑制剂预防或减轻眼痛的方法。
-
公开(公告)号：US06696453B2
公开(公告)日：2004-02-24
申请号：US10150219
申请日：2002-05-17
申请人： Daniel A. Gamache , John M. Yanni
发明人： Daniel A. Gamache , John M. Yanni
IPC分类号： A61K31505
CPC分类号： A61K31/505 , A61K31/00 , A61K31/165 , A61K31/166 , A61K31/395 , Y10S514/912
摘要： NF-&kgr;B inhibitors are useful for treating dry eye disorders and other disorders requiring the wetting of the eye.
摘要翻译： NF-κB抑制剂可用于治疗需要润湿眼睛的干眼病和其它病症。
-
9.发明授权公开(公告)号：US08541389B2
公开(公告)日：2013-09-24
申请号：US13035147
申请日：2011-02-25
申请人： John M. Yanni , Jon E. Chatterton , Diane Michelle Senchyna , Daniel A. Gamache , Steven T. Miller
发明人： John M. Yanni , Jon E. Chatterton , Diane Michelle Senchyna , Daniel A. Gamache , Steven T. Miller
IPC分类号： C12N15/11
CPC分类号： C12N15/1138 , A61K31/7088 , A61K31/713 , C12N15/1137 , C12N2310/14 , C12N2310/346 , C12N2310/351 , C12N2320/30
摘要： RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk of developing a TNFα-related condition such as the ocular conditions dry eye, allergic conjunctivitis, or ocular inflammation, or such as dermatitis, rhinitis, or asthma, for example.
摘要翻译： 通过沉默TNFα细胞表面受体TNF受体-1（TNFR1）mRNA表达或沉默TNFα转化酶（TACE / ADAM17）mRNA表达，提供RNA干扰抑制肿瘤坏死因子α（TNFalpha）。 特别是沉默这种TNFα靶标，可用于治疗患有TNFalpha相关病症或有发生TNFalpha相关病症风险的患者，如眼病干眼症，过敏性结膜炎或眼部炎症，或诸如皮炎，鼻炎 ，或哮喘。
-
10.发明授权公开(公告)号：US08222227B2
公开(公告)日：2012-07-17
申请号：US13173512
申请日：2011-06-30
IPC分类号： C12N15/11
CPC分类号： C12N15/1138 , C12N2310/111 , C12N2310/14 , C12N2310/141
摘要： RNA interference is provided for inhibition of histamine receptor H1 mRNA expression, in particular, for treating patients having an HRH1-related condition or at risk of developing an HRH1-related condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, or allergy.
摘要翻译： 提供RNA干扰用于抑制组胺受体H1mRNA表达，特别是用于治疗患有HRH1相关病症或具有发生HRH1相关病症的风险的患者，例如过敏性结膜炎，眼部炎症，皮炎，鼻炎，哮喘或 过敏。
-
-
-
-
-
-
-
-
-
搜索结果
68 条记录 (耗时 0.041 秒)
